Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Coffey

Showing results (491-500 of 512) with videos related to

Pageof 52
Sort By:
Neurology|February 28, 2020
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?Alberto J Espay, Lorraine V Kalia, Ziv Gan-Or, et al.
Cancer|May 6, 2021
Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patientsWilliam R Ryan, Mary J Xu, Edgar Ochoa, et al.
Annals of Neurology|November 20, 2018
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic StrokePatrick Lyden, Kent E Pryor, Christopher S Coffey, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 28, 2026
Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification AssaySarah M Brooker, Jacopo Pasquini, Seung Ho Choi, et al.
BMC Pregnancy and Childbirth|September 23, 2015
Count every newborn; a measurement improvement roadmap for coverage dataSarah G Moxon, Harriet Ruysen, Kate J Kerber, et al.
Journal of Neuropathology and Experimental Neurology|August 15, 2018
Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)Thomas G Beach, Geidy E Serrano, Thomas Kremer, et al.
Neuro-Oncology Advances|January 28, 2022
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trialCorinne E Griguer, Claudia R Oliva, Christopher S Coffey, et al.
JCO Oncology Practice|December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck ConsortiumAllen S Ho, Justin T Moyers, Shirin Attarian, et al.
Pageof 52

Showing results (491-500 of 512) with videos related to

Sort By:
Pageof 52
Neurology|February 28, 2020
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?Alberto J Espay, Lorraine V Kalia, Ziv Gan-Or, et al.
Cancer|May 6, 2021
Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patientsWilliam R Ryan, Mary J Xu, Edgar Ochoa, et al.
Annals of Neurology|November 20, 2018
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic StrokePatrick Lyden, Kent E Pryor, Christopher S Coffey, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 28, 2026
Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification AssaySarah M Brooker, Jacopo Pasquini, Seung Ho Choi, et al.
BMC Pregnancy and Childbirth|September 23, 2015
Count every newborn; a measurement improvement roadmap for coverage dataSarah G Moxon, Harriet Ruysen, Kate J Kerber, et al.
Journal of Neuropathology and Experimental Neurology|August 15, 2018
Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)Thomas G Beach, Geidy E Serrano, Thomas Kremer, et al.
Neuro-Oncology Advances|January 28, 2022
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trialCorinne E Griguer, Claudia R Oliva, Christopher S Coffey, et al.
JCO Oncology Practice|December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck ConsortiumAllen S Ho, Justin T Moyers, Shirin Attarian, et al.
Pageof 52